Biomatter
PrivateLast Round
Series A
Nov 12, 2026
Total Funding Raised
$25.74M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Biomatter operates in Healthcare & Life Sciences and is based in Vilnius. Its latest recorded funding round was a Series A round in November 2026.
Biomatter is a synthetic biology company that has developed an AI-powered platform to design and create new proteins and enzymes for applications in medicine, agriculture, and chemical biomanufacturing.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, ML Platforms
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share, Subscription SaaS
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biomatter Comparables
Compare Biomatter with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Evozyne | 89% | |
| Allozymes | 86% | |
| Zymvol Biomodeling | 84% |
For institutional investors. Book with your work email.
Biomatter Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Nov 12, 2026 | ||||
| Seed | Aug 5, 2024 | ||||
| Seed | Jan 11, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biomatter Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Astanor Ventures | Series A |
| Metaplanet Holdings | Seed |
| Practica Capital | Seed |
| Inventure | Series A, Seed |
| 70V | Seed |
| UVC Partners | Series A, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 12, 2026
$18M round led by Astanor Ventures.
- Aug 21, 2026
Monthly visitors grew 37% MoM, from 2.2K to 3K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- invests_into_assetsNov 12, 2026
Biomatter Inc. plans to use the investment to open a 2,000 m^2 design and testing facility in Vilnius, Lithuania, in 2027.
- expands_offices_inNov 12, 2026
Biomatter Inc. plans to expand its commercial team and presence in the United States, where roughly half of its customers are based.
- expands_facilitiesNov 12, 2026
Biomatter Inc. plans to establish a 2,000-square-metre enzyme design and testing facility in Vilnius, scheduled to open in 2027, to bring more development and testing activities in-house.
- receives_financingNov 12, 2026
Biomatter Inc. receives $18M in an oversubscribed Series A round led by Astanor, with participation from existing investors UVC Partners, Inventure and Metaplanet, to accelerate AI-powered enzyme development on Nov 12th '26.
For institutional investors. Book with your work email.
Biomatter Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biomatter's valuation, stock price, and market status.
Is Biomatter a public or private company?
Biomatter is a private company.
What is the current stock price of Biomatter?
Biomatter is a private company, so its shares have no public market price. Caplight tracks Biomatter's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biomatter worth (valuation)?
Valuation information for Biomatter is not publicly available.
Can I buy Biomatter stock?
Biomatter shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biomatter's last funding round?
Biomatter's most recent funding round was Series A on November 12, 2026.
Who are the main investors in Biomatter?
Key investors in Biomatter include Astanor Ventures, Practica Capital, Inventure, UVC Partners.
Will Biomatter IPO soon?
No public IPO plans have been announced for Biomatter.
How can I track Biomatter secondary market activity?
Caplight tracks bids, offers, and trades in Biomatter's shares on secondary markets.